Abstract
Two recent studies demonstrate the power of integrating tumor genotype information with epigenetic and proteomic studies to discover potential therapeutic targets in breast cancer.
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use*
-
Atlases as Topic
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology
-
Drug Resistance, Neoplasm / genetics
-
Epigenesis, Genetic*
-
Female
-
Gene Expression Regulation, Neoplastic*
-
Genome, Human
-
High-Throughput Nucleotide Sequencing
-
Humans
-
Mice
-
Molecular Targeted Therapy
-
Phosphatidylinositol 3-Kinase / genetics*
-
Phosphatidylinositol 3-Kinase / metabolism
-
Phosphoinositide-3 Kinase Inhibitors
-
Receptor, ErbB-2 / antagonists & inhibitors
-
Receptor, ErbB-2 / genetics
-
Receptor, ErbB-2 / metabolism
-
Thiazoles / therapeutic use*
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents
-
Phosphoinositide-3 Kinase Inhibitors
-
Thiazoles
-
Alpelisib
-
Phosphatidylinositol 3-Kinase
-
ERBB2 protein, human
-
Receptor, ErbB-2